Skip to main content
Yu Mi Kang, MD, Endocrinology, Boston, MA

Yu MiKangMDPhD(She/Her)

Endocrinology • Boston, MA

Diabetes, Lipid Metabolism, Obesity

Division of Endocrinology, Diabetes and Hypertension, Harvard Medical School/Brigham and Women's Hospital

Join to view full profile

Dr. Kang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Kang's full profile

Already have an account?

Summary

  • Clinical areas of experience include management of diabetes, obesity, and metabolic disorders. Research interests are (1) investigating the prognosis of various cardiometabolic conditions including type 2 diabetes and obesity through big-data analyses and (2) cardiovascular effects of novel antidiabetic therapies such as DPP4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors.

Education & Training

  • Bridgeport Hospital/Yale University
    Bridgeport Hospital/Yale UniversityResidency, Internal Medicine, 2019 - 2022
  • Bridgeport Hospital/Yale University
    Bridgeport Hospital/Yale UniversityInternship, Internal Medicine, 2019 - 2020
  • University of Ulsan College of Medicine
    University of Ulsan College of MedicinePh.D., Internal Medicine / Cardiovascular diabetology, 2013 - 2015
  • Other
    OtherClass of 2010, MD-MSc
  • University of Toronto
    University of TorontoB.Sc., Integrative Biology, 2002 - 2005

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2021 - 2025
  • CT State Medical License
    CT State Medical License 2019 - 2022
  • American Board of Internal Medicine Internal Medicine
  • Korean Endocrine Society Board Certification of Endocrinology
  • The Korean Association of Internal MedicineBoard of Internal Medicine

Awards, Honors, & Recognition

  • Outstanding Abstract Award Endocrine Society, 2021
  • Hospitalist Choice Award Internal Medicine, Yale New Haven Health: Bridgeport Hospital, 2020
  • Platinum Certificate of Appreciation Yale New Haven Health, 2019
  • Join now to see all

Publications & Presentations

PubMed

Lectures

  • Cardiovascular Fate of Metabolically Healthy Obesity (MHO): Is it Really a Benign Condition? 
    International Vascular Biology Meeting - 9/2020
  • Beneficial effects of adipocytokines in preventing arteriosclerosis 
    Asia-Oceania Conference on Obesity (AOCO) 2017 - 10/4/2017

Grant Support

  • Korean Diabetes Prevention Study - Pilot projectKorean Center for Disease Control2015–2016

Committees

  • Vice Secretary, Scientific Committee, Korean Society of Lipid and Atherosclerosis 2019 - Present
  • Vice Secretary, Scientific Committee, Korean Society for the Study of Obesity 2016 - 2018

Research History

  • Characterization of diabetic population in KoreaUtilizing a national cohort in Korea, ran clinical and translational research topics on characterizing a diabetic population and predicting cardiometabolic and mortality outcomes.2016 - 2019
  • Safety and effect of incretin-based antidiabetic medicationsInvolved different forms of research such as direct clinical trial (DPP4 inhibitors), meta-analyses, and reviews. Emphasis was on the ethnic difference.2015 - 2019
  • Characterization of metabolically healthy obese populationClinical and translational research topics on characterizing a metabolically healthy obese (MHO) population and predicting cardiometabolic and mortality outcomes.2015 - 2019

Professional Memberships

  • Korean Diabetes Association
    Member
  • Korean Endocrine Society
    Member
  • Korean Society of Lipid and Atherosclerosis
    Member
  • Korean Society for the Study of Obesity
    Member
  • European Association for the Study of Diabetes
    Member
  • American Diabetes Association - ADA
    Member
  • Endocrine Society
    Member

Other Languages

  • Korean

Dr. Yu Mi Kang, Dr. Yu Mi Kang, MD, Dr. Y Kang